COL6A2

Across TCGA pan-cancer cohorts, COL6A2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated COL6A2 data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher COL6A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated COL6A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

THCA, UCEC, and LIHC are the cancer types where COL6A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.425	0.898	<.001	43	view →
UCEC	DFS	Median	All	0.950	0.825	.012	26	view →
LIHC	DFS	Median	All	0.103	0.557	<.001	18	view →
READ	OS	Median	III,IV	0.644	0.932	<.001	16	view →
BLCA	OS	Median	II,III,IV	1.000	0.701	.030	8	view →
LUAD	OS	Median	III,IV	0.004	0.662	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.869	0.676	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

COL6A2–THCA (DFS)

Open the THCA breakdown →